CDK4 and liver cancer: found that glabridin can significantly inhibit the expression of cyclin-dependent kinase 2 (CDK2), cyclin-dependent kinase 4 (CDK4), and G1/S-specific cyclin D3(cyclin D3), blocking the cell cycle at the G1 phase, thereby inhibiting the proliferation of liver cancer cells (92).